Exact Sciences: Profitability Remains Elusive

(12min)

Summary

  • Exact Sciences Corporation's revenue growth is strong, but high expenses have prevented profitability to this point, with expected losses on a non-GAAP basis through 2025.
  • The company's main product, Cologuard, faces competition from Geneoscopy's ColoSense, despite the upcoming launch of the improved Cologuard Plus.
  • Exact's stock has been highly volatile, influenced by revenue misses and downward revisions, despite positive EBITDA growth and its CEO's recent stock purchase.
  • An analysis around Exact Sciences follows in the paragraphs below.
  • Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More »

Disease Cognostics Laboratory

SolStock

Shares of cancer screening concern Exact Sciences Corporation (NASDAQ:EXAS) have been on multiple rollercoaster rides over the past four and a half years as top and bottom lines fail to match up. The company is expected to generate FY25

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

51.15K Followers

Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.

Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About EXAS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on EXAS

Related Stocks

SymbolLast Price% Chg
EXAS
--